HighTower Advisors LLC Sells 4,236 Shares of Eli Lilly and Company $LLY

Key Points

• HighTower Advisors reduced its Eli Lilly position by 1.0%, selling 4,236 shares and retaining 436,561 shares valued at approximately $523.6 million. Institutional investors and hedge funds collectively own 82.53% of the stock.
• Eli Lilly reported strong quarterly results, with adjusted EPS of $8.38 versus the $6.40 consensus estimate and revenue of $22.97 billion, up 47.7% year over year. Growth is being driven by GLP-1 and obesity treatments, including pipeline candidate retatrutide.
• Wall Street maintains a favorable view, with a consensus rating of “Moderate Buy” and an average price target of $1,292.18. However, the stock’s premium valuation, competition and pricing pressure remain key risks, while recent executive sales were conducted under pre-arranged Rule 10b5-1 plans.

HighTower Advisors LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 1.0% in the second quarter, according to its most recent filing with the SEC. The firm owned 436,561 shares of the company's stock after selling 4,236 shares during the period. HighTower Advisors LLC's holdings in Eli Lilly and Company were worth $523,625,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. NorthStar Asset Management LLC NJ increased its stake in Eli Lilly and Company by 5.8% in the second quarter. NorthStar Asset Management LLC NJ now owns 2,587 shares of the company's stock valued at $3,103,000 after acquiring an additional 141 shares during the period. BLB&B Advisors LLC raised its position in Eli Lilly and Company by 479.3% in the second quarter. BLB&B Advisors LLC now owns 10,670 shares of the company's stock worth $12,798,000 after purchasing an additional 8,828 shares in the last quarter. Convergence Financial LLC lifted its stake in Eli Lilly and Company by 95.1% during the second quarter. Convergence Financial LLC now owns 8,507 shares of the company's stock worth $10,204,000 after purchasing an additional 4,147 shares during the period. TBH Global Asset Management LLC lifted its stake in Eli Lilly and Company by 24.5% during the second quarter. TBH Global Asset Management LLC now owns 3,133 shares of the company's stock worth $3,757,000 after purchasing an additional 616 shares during the period. Finally, SFE Investment Counsel boosted its holdings in Eli Lilly and Company by 2.5% during the second quarter. SFE Investment Counsel now owns 5,971 shares of the company's stock valued at $7,162,000 after purchasing an additional 144 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Weight-loss leadership remains a key catalyst. Eli Lilly was highlighted as an IBD Stock of the Day as its obesity-drug business gains ground on Novo Nordisk. Investor attention is also focused on the company’s next-generation obesity candidate retatrutide following encouraging trial-related developments. Eli Lilly, Stock Of The Day, Is Erasing Novo's Early Lead In Weight-Loss Pills
• Positive Sentiment: Recent quarterly results support the bullish outlook. Lilly’s latest reported quarter substantially exceeded earnings and revenue expectations, with revenue up 47.7% year over year. Analysts cited GLP-1 momentum, a broad pipeline and strong operating growth as reasons for continued long-term momentum. LLY Up Around 6% Post Robust Q2 Results
• Positive Sentiment: Pipeline expansion continued through partnerships. Lilly signed a global collaboration and licensing agreement with OmniAb for an ion-channel drug-discovery program, potentially providing access to new medicines. It also made a $10 million upfront payment to AlzeCure for rights connected to small-molecule CNS treatments, including Alzheimer’s and pain candidates. OmniAb Enters Collaboration and License Agreement with Eli Lilly
• Neutral Sentiment: International execution is progressing. Lilly appointed Tayllit Aherdan to lead operations in the United Arab Emirates, Qatar and Kuwait, supporting its commercial expansion in the Middle East. Lilly Appoints Tayllit Aherdan
• Negative Sentiment: Valuation and competition remain risks. Analysts noted that Lilly’s premium valuation leaves less room for execution misses, while competition, pricing pressure and future obesity-drug rivals could moderate upside.
• Negative Sentiment: An executive sale adds a minor sentiment headwind. EVP Patrik Jonsson sold 6,500 shares worth approximately $7.6 million. However, the transaction was made under a pre-arranged Rule 10b5-1 plan, reducing its significance as a discretionary bearish signal. SEC Insider Transaction Filing

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Cantor Fitzgerald upped their price objective on Eli Lilly and Company from $1,350.00 to $1,410.00 and gave the company an "overweight" rating in a research note on Thursday, August 6th. Jefferies Financial Group raised their target price on Eli Lilly and Company from $1,330.00 to $1,350.00 and gave the stock a "buy" rating in a research report on Tuesday, June 9th. Wolfe Research reaffirmed an "outperform" rating and issued a $1,350.00 price target on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Leerink Partners upped their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an "outperform" rating in a research report on Thursday, June 25th. Finally, Bank of America increased their price objective on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a "buy" rating in a research note on Friday, July 10th. One research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $1,292.18.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the firm's stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total value of $5,950,000.00. Following the transaction, the executive vice president owned 11,875 shares of the company's stock, valued at approximately $14,131,250. This trade represents a 29.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm's stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the completion of the transaction, the executive vice president directly owned 54,147 shares in the company, valued at $63,628,139.70. This trade represents a 10.72% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 13,500 shares of company stock worth $15,958,170. Company insiders own 0.14% of the company's stock.

Eli Lilly and Company Stock Up 3.7%

NYSE LLY opened at $1,227.11 on Wednesday. The stock has a fifty day moving average of $1,173.20 and a 200-day moving average of $1,055.15. The stock has a market capitalization of $1.16 trillion, a P/E ratio of 41.18, a price-to-earnings-growth ratio of 1.39 and a beta of 0.51. Eli Lilly and Company has a 52 week low of $685.15 and a 52 week high of $1,249.45. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.40 by $1.98. The business had revenue of $22.97 billion for the quarter, compared to analyst estimates of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The firm's revenue for the quarter was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, equities research analysts forecast that Eli Lilly and Company will post 36.35 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company's dividend payout ratio is presently 23.22%.

Eli Lilly and Company Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source